The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Severe hypertriglyceridemia (≥500 mg/dl [5.65 mmol/l]) should be treated to reduce the risk of pancreatitis. The omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA ...

The global cholesterol and lipid test market value is anticipated to expand from USD 3.0 billion in 2024 to USD 6.2 billion ...

It’s important to remember that many of these medications only work when you take them along with lifestyle measures, such as a balanced, nutritious diet. If you have high triglyceride levels, a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Waylivra (volanesorsen) is now likely to become the first available treatment for familial chylomicronemia ... and characterised by severe hypertriglyceridemia and a risk of unpredictable and ...

Phenylephrine hydrochloride is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Pre-Market: 8:00:00 a.m. EST ...